Cereno Scientific reports positive Phase I PK bridging study results
1 report, 1 independent
Updated Fri 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cereno Scientific reported positive topline results from a Phase I pharmacokinetic bridging study of its HDAC inhibitor CS014. The study, which was conducted in Sweden, met the company's predefined expectations. The results support the strategy to advance CS014 directly toward Phase IIb, pending review of the complete Investigational New Drug package by the FDA.
From finanznachrichten.de
Why it matters
The positive results strengthen the company's intended regulatory strategy to move directly to a Phase IIb trial. This progress could accelerate the development timeline for treatments aimed at rare cardiovascular and pulmonary diseases, subject to regulatory approval.
From finanznachrichten.de
Who's involved
Keep exploring
The entities involved
Related events
- NewcelX Ltd. advanced its IND-enabling work for a Phase 1/2a trial and held a successful Type B Pre-IND meeting with the FDA.
- The FDA placed a clinical hold on the IND application for the company Aardvark.
- A study protocol involving a company based in Mont-Saint-Guibert was approved by the U.S. FDA.
- OS Therapies, Inc. is seeking interim and final review data submissions from regulatory bodies while attending major global investment conferences.
- Emmaus Life Sciences is conducting Phase 3 trials for an Endari drug, preceding future FDA submission.